AMELION: A Randomized, Double Blinded, Phase 2, Efficacy and Safety Study of Abituzumab (EMD 525797) in Combination With Cetuximab and FOLFIRI Versus Placebo in Combination With Cetuximab and FOLFIRI in First-line RAS Wild-type, Left-sided, Metastatic Colorectal Cancer Patients With High ανβ6 Integrin Expression.
The purpose of this study is to evaluate the safety and efficacy of the experimental drug abituzumab (EMD525797) in combination with cetuximab and FOLFIRI in RAS wild-type, left-sided, metastatic colorectal cancer patients with high ανβ6 integrin expression.
100 项与 SFJ Pharmaceuticals X, LTD. 相关的临床结果
0 项与 SFJ Pharmaceuticals X, LTD. 相关的专利（医药）
100 项与 SFJ Pharmaceuticals X, LTD. 相关的药物交易
100 项与 SFJ Pharmaceuticals X, LTD. 相关的转化医学
